Loading clinical trials...
Loading clinical trials...
The Reversal of Residual Neuromuscular Blockade After Neostigmine and Half-dose Sugammadex: A Comparison With Standard Reversal of Full-dose Neostigmine
Conditions
Interventions
Neostigmine
Sugammadex
Start Date
May 1, 2013
Primary Completion Date
October 1, 2016
Completion Date
December 30, 2016
Last Updated
October 4, 2021
NCT07404579
NCT07371377
NCT04524585
NCT06409260
NCT05886218
NCT06945341
Lead Sponsor
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions